Monday, 25 Sep 2017

You are here

1 September 2017: The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report includes new data on IL-1 inhibition and protection from CV events and lung cancer, baricitinib given a reprieve, and features on infections - HBV, shingles and mortality of septic arthritis.

Please donate something/anything to American Red Cross to help victims of Hurricaine Harvey. I did! Every bit helps https://t.co/CmlDWfRX6R  or text HARVEY to 90999 to donate $10.

Watch for RheumNow’s novel new coverage of the 2017 ACR meeting from San Diego! We'll have a microsite dedicated to the meeting, and multiple RN faculty will report on site, providing pics, tweets, articles and videos from leading rheumatologists. 

  1. 25 studies shows low risk of HBV reactivation (1.6%) w/ resolved HBV - not changed by TNFi, other biologics, DMARDs https://t.co/wzjikRHPFh  
  2. 1667 geriatric pts w/ Septic arthritis matched 1:10 w/o; those w/ Septic arthritis had 50-100% increase mortality https://t.co/LcMpdKT6pI
  3. RT @NYTHealth: FDA announces crackdown on "unscrupulous" stem cell clinics. https://t.co/uQajkkZF5x
  4. Severe (ocular) Behcets study: ~half respond to TNF inhib but only half these stay in remission w/ TNFi withdrawal https://t.co/a2oGZADlle
  5. Epidemiology of SLE varied but incidence appears to be increasing. Highest frequencies in AA, N America (23/100K-PY); lowest in Africa, Ukraine, N. Australia https://t.co/jK9tJ2Ybqy
  6. Untreated Sleep apnea increases free fatty acids, glucose, cortisol and blood pressure during sleep. https://buff.ly/2eHGiay
  7. FDA approves 1st gene therapy - CAR T-cell therapy approved B-cell acute lymphoblastic leukemia https://t.co/wPNHbQIhwx
  8.  FDA Approves Genentech’s Actemra (tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome - https://t.co/hGJcWyZEy5
  9. Turnabout for Baricitinib  
  10. Another Adalimumab Biosimilar Approved 
  11. Canakinumab Reduces CV Outcomes in High Risk Patients  
  12. Canakinumab Patients have Lower Risk of Lung Cancer
  13. Shingles Vaccine Studies in A&R  
  14. Therapeutic Update:  See what Drs. Mease, Gibofsky, Cush have to say about FDA hearing on Tofacitinib for Psoriatic Arthritis 
  15. The job is not you, nor is your income, car or good looks. You are your principles and what you do when those principles are needed.  Listen to this podcast by Malcolm Gladwell

 

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

22 September 2017 The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses survey results on membranous nephritis and patient perceptions of steroids, nonadherence, celebrity arthritis and IgG4 treatment.

CDC: 40% of U.S Adults Claim to Have Arthritis

The CDC has reported its 2013 and 2014 prevalence statistics for arthritis and other chronic medical conditions affecting U.S. adults aged ≥18 years. Data is drawn from the ongoing Behavioral Risk Factor Surveillance System (BRFSS), a state-based, telephone survey of noninstitutionalized adults. Data herein is self-reported arthritis (OA, RA, Gout, FM) and is quantified by state and metropolitan areas.

15 September 2017 The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses metabolic syndrome in lupus, bisphosphonate holidays, vasculitis and vascular inflammation, vaccination, and the repeated wonders of Vitamin D.

Why Rheumatologists Should Do Better Vaccinating this Flu Season

It is well known that influenza infection is more common in patients with rheumatologic diseases. Blumentals et al. showed that patients with rheumatoid arthritis are at increased risk for influenza regardless of DMARD/biologic use and may have a 2.75-fold increased incidence of related complications (https://buff.ly/2gYNTSz).

8 September 2017: The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report includes trends in MTX use and outcomes, fibromyalgia as an inflammatory disorder, drugs that stop psoriasis pruritus, drugs that don't cause TB, cardiovascular risk, and what Rheums think of ACR/EULAR criteria.